IPO Date: Jul 9 to Jul 11 2025
Listing Date: Jul 16 2025
1. Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit;
2. Funding the incremental working capital requirements of our Company;
3. Repayment and/or prepayment, in part or full, of certain of our outstanding borrowings availed by ourCompany; and
4. General Corporate Purposes
...
African markets. Our Company operates under brand “Asston”. Presently, our Company is involved in thebusiness of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel andLotion) and Oral Powder (Sachet, Dry Syrup) etc. Apart from manufacturing products for direct sales, our Company alsomanufactures various pharmaceutical products for different marketers on loan license or on contract manufacturing basis. Ourbusiness is primarily conducted on a principle-to-principle basis with various marketers.As on the date, we cater to multiple corporate clients on loan licence and/or contract manufacturing basis. Currently, our Companyhas its production facility at Ambernath, Maharashtra, for producing generic medicines in the tablet form and nutraceuticalmedicines in the tablet form, syrup and sachet form. We have a dedicated and separate floors for pharmaceutical products andnutraceutical products respectively as the norms and standards are different for both of them and are governed by FDA and FSSAIrespectively. Since the FDA norms for pharmaceutical products are much more stringent, to comply with FDA standards separateguidelines are there to be followed. Facility has total production capacity of up to around 8-9 crore tablets per month. Our Companyproduces an average of 5-6 crore tablets per month, with production capacity varying based on the weight of the medicines. Higherweightmedicines result in lower production quantities and vice versa. The syrup production capacity for nutraceuticals isapproximately 37.5 kiloliters per month, while sachet production capacity ranges from 30 to 40 lakh sachets per month, dependingon the powder weight per sachet. The facility is certified by relevant authorities and undergoes periodic audits by state and centralFDA authorities. It includes a QA/QC unit and a warehouse for storing raw materials and finished goods in designated chambersunder controlled conditions. Our Company engages contract manufacturers to produce generic medicines and antibiotics in variousforms, including tablets, sachets, syrups, and capsules. All contract manufacturers are WHO-GMP certified to ensure their facilitiesand processes comply with applicable standards and industry norms. Read More
Posted on Jan 3rd
India Homes informs about disclosure
Posted on Jan 2nd
Modi government could give neither clean water, nor clean air, making public suffer: Mallikarjun Kharge
Posted on Jan 2nd
Gabion Technologies India coming with IPO to raise Rs 29.16 crore
Posted on Jan 2nd
Currency futures for January expiry trade tad stronger with 3.02% decrease in OI
The issue size of Asston Pharmaceuticals Ltd. IPO is ₹18.47 - 19.75 crore.
The Asston Pharmaceuticals Ltd. IPO opens for subscription on 2025-07-09 and closes on 2025-07-11.
The price range of Asston Pharmaceuticals Ltd. IPO is ₹115.00 to ₹123.00.
The lot size of Asston Pharmaceuticals Ltd. IPO is 2000 shares.
The registrar of Asston Pharmaceuticals Ltd. IPO is Maashitla Securities Pvt Ltd..
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.